Selected References
- Blandthorn J, et al. 2018. Managing opioid overdose in pregnancy with take-home naloxone. Aust N Z J Obstet Gyneacol 58(4):460-62.
- Debelak K, et al. 2013. Buprenorphine + Naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict; 22(3):252-54.
- Flannagan KS, et al. 2020. Prescription opioid use among populations of reproductive age: effects on fertility, pregnancy loss, and pregnancy complications. Epidemiologic reviews. 42(1): 117-33.
- Gawronski KM, et al. 2014. Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone. 2:2050312114530282.
- Goshgarian G, et al. Prenatal Buprenorphine/Naloxone or Methadone Use on Neonatal Outcomes in Michigan. Cureus.14(8).
- Griffiths S, et al. 2021. Use of injectable opioid agonist therapy in a in-patient setting for a pregnant patient with opioid use disorder: A case report. Journal of Addiction Medicine. 15(5): 435-38.
- Jones HE & Kraft WK. 2019. Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. Clin Perinatol; 46(2):349-366.
- Jansson LM, et al. 2024. Buprenorphine-Naloxone Maintenance and Lactation. Journal of Human Lactation 40(1): 113-19.
- Jumah NA, et al. 2016. Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population. BMJ Open; 6(10):e011774.
- Kanervo M, et al. 2023. Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder. Acta Obstetricia et Gynecologica Scandinavica. 102(3): 313-22.
- Kanervo M, et al. 2024. Intrauterine exposure to maternal opioid maintenance treatment and associated risk factors may impair child growth. Acta Paediatrica.
